Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression
Interventions: citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine); Drug · Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 41
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more

Conditions: Major Depressive Disorder
Interventions: Tai Chi; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Healthy Control; Drug · Other
Lead sponsor: Wyss Institute at Harvard University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Chronic Major Depression, Recurrent
Interventions: Sertraline; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacogenetics, Depressive Disorder, Major, Medication Therapy Management
Interventions: Pharmacogenomic Screening; Other
Lead sponsor: Auburn University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Depressive Disorder, Major
Interventions: Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 18
States / cities: Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: Opioid Use Disorder, Major Depressive Disorder (MDD)
Interventions: Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Major Depressive Disorder
Interventions: Duloxetine hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 43
States / cities: Beverly Hills, California • Escondido, California • National City, California + 40 more

Conditions: Major Depressive Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: Neuronetics; Other
Eligibility: 18 Years to 70 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Poway, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Schizophrenia, Major Depression, Bipolar Disorder, PTSD
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Up to 120 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depressive Symptoms, Clinical Depression
Interventions: Road Tour, Boatload of Crosswords; Other
Lead sponsor: Marianne Smith; Other
Eligibility: 55 Years and older
Enrollment: 351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 32
States / cities: Amana, Iowa • Bettendorf, Iowa • Carlisle, Iowa + 17 more

Conditions: Major Depressive Disorder, Bipolar Disorder
Interventions: Not listed
Lead sponsor: Affective Neuroscience Laboratory; Other
Eligibility: 18 Years to 64 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more

Conditions: Major Depressive Disorder, Epilepsy
Interventions: Intracranial electrodes, TMS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depressive Disorder, Major
Interventions: 5 mg BI 1569912, 20 mg BI 1569912, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Garden Grove, California • Torrance, California • Miami, Florida + 7 more

Conditions: Major Depressive Disorder
Interventions: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs); Drug
Lead sponsor: Adams Clinical; Network
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
Interventions: Ketamine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depression
Interventions: CURB; Behavioral
Lead sponsor: Benjamin Van Voorhees, MD, MPH; Other
Eligibility: 13 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Assay-guided treatment (AGT), Treatment-as-usual (TAU); Genetic · Other
Lead sponsor: Genomind, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more

Conditions: Major Depression
Interventions: quetiapine (Seroquel XR); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depressive Disorder, Major, Postpartum Depression
Interventions: Dyadic Interpersonal Psychotherapy, Enhanced Treatment as Usual; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Mobile-device, plasticity-based adaptive cognitive treatment; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Depression
Interventions: EPA omega-3 fatty acid, DHA omega-3 fatty acid, Placebo comparator; Dietary Supplement
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Tai Chi Training for Treating Depressed Chinese Americans

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Exploring Biomarkers for Depression

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder

Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core

Improving Mood in Assisted Living Settings

Behavioral Processes Underlying Reward Processing in Depression

A Trial of AXS-05 in Patients With Major Depressive Disorder

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study

The UTHealth Ketamine Project

Chicago Urban Resiliency Building (CURB)

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

Brain Imaging of Quetiapine Response in Anxious Depression

Mommy-Baby Treatment for Perinatal Depression

A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety

Omega-3 Fatty Acids for Treating Adults With Major Depression